KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Sales (2019 - 2025)

Esperion Therapeutics' Return on Sales history spans 7 years, with the latest figure at 0.37% for Q4 2025.

  • For Q4 2025, Return on Sales rose 79.0% year-over-year to 0.37%; the TTM value through Dec 2025 reached 0.06%, down 2.0%, while the annual FY2025 figure was 0.06%, 10.0% up from the prior year.
  • Return on Sales reached 0.37% in Q4 2025 per ESPR's latest filing, up from 0.37% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.42% in Q1 2024 to a low of 11.4% in Q1 2021.
  • Average Return on Sales over 5 years is 2.17%, with a median of 1.52% recorded in 2023.
  • Peak YoY movement for Return on Sales: soared 3133bps in 2021, then plummeted -246bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 4.48% in 2021, then skyrocketed by 33bps to 3.02% in 2022, then soared by 41bps to 1.78% in 2023, then skyrocketed by 76bps to 0.42% in 2024, then soared by 188bps to 0.37% in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Return on Sales are 0.37% (Q4 2025), 0.37% (Q3 2025), and 0.16% (Q2 2025).